Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pretreatment neutrophil to lymphocyte ratio as prognostic factor in metastatic breast cancer treated with cyclin dependent kinase 4/6 inhibitors.
Rottier P, Emile G, Johnson A, Levy C, Allouache D, Hrab I, Segura C, Morel A, Villemin M, Dubot-Poitelon C, Boismoreau L, Cherifi F, Lequesne J, Da Silva A. Rottier P, et al. Among authors: hrab i. Front Oncol. 2023 Jan 19;12:1105587. doi: 10.3389/fonc.2022.1105587. eCollection 2022. Front Oncol. 2023. PMID: 36741710 Free PMC article.
HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer.
Cherifi F, Da Silva A, Johnson A, Blanc-Fournier C, Abramovici O, Broyelle A, Levy C, Allouache D, Hrab I, Segura C, Morel A, Villemin M, Boscher C, Dubot-Poitelon C, Rottier P, Lequesne J, Emile G. Cherifi F, et al. Among authors: hrab i. BMC Cancer. 2022 Oct 20;22(1):1081. doi: 10.1186/s12885-022-10163-9. BMC Cancer. 2022. PMID: 36266623 Free PMC article.
Association between physical activity and neoadjuvant chemotherapy completion and pathologic complete response in primary breast cancer: the CANTO study.
Baker JL, Di Meglio A, Gbenou AS, El Mouhebb M, Iyengar NM, Michiels S, Cottu P, Lerebours F, Coutant C, Lesur A, Tredan O, Vanlemmens L, Jouannaud C, Hrab I, Everhard S, Martin AL, Arveux P, Fabrice A, Vaz-Luis I, Jones LW. Baker JL, et al. Among authors: hrab i. Br J Cancer. 2022 Sep;127(5):886-891. doi: 10.1038/s41416-022-01870-y. Epub 2022 Jun 17. Br J Cancer. 2022. PMID: 35715631 Free PMC article.
REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours.
Lévy C, Allouache D, Lacroix J, Dugué AE, Supiot S, Campone M, Mahe M, Kichou S, Leheurteur M, Hanzen C, Dieras V, Kirova Y, Campana F, Le Rhun E, Gras L, Bachelot T, Sunyach MP, Hrab I, Geffrelot J, Gunzer K, Constans JM, Grellard JM, Clarisse B, Paoletti X. Lévy C, et al. Among authors: hrab i. Ann Oncol. 2015 Nov;26(11):2359. doi: 10.1093/annonc/mdv386. Ann Oncol. 2015. PMID: 26504187 Free article. No abstract available.
How to improve the prevention of chemotherapy-induced nausea and vomiting? The French NAVI study.
Vanbockstael J, Coquan E, Gouerant S, Allouache D, Faveyrial A, Noal S, Delcambre C, Galais MP, Héron JF, Lefebvre AC, Sevin E, Hrab I, Polycarpe F, André M, Kaluzinski L, Gervais R, Gunzer K, Vié B, Saucier G, Lemenand N, Grellard JM, Clarisse B, Dugué AE, Joly F. Vanbockstael J, et al. Among authors: hrab i. Support Care Cancer. 2016 Mar;24(3):1131-8. doi: 10.1007/s00520-015-2882-7. Epub 2015 Aug 14. Support Care Cancer. 2016. PMID: 26268784
REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours.
Lévy C, Allouache D, Lacroix J, Dugué AE, Supiot S, Campone M, Mahe M, Kichou S, Leheurteur M, Hanzen C, Dieras V, Kirova Y, Campana F, Le Rhun E, Gras L, Bachelot T, Sunyach MP, Hrab I, Geffrelot J, Gunzer K, Constans JM, Grellard JM, Clarisse B, Paoletti X. Lévy C, et al. Among authors: hrab i. Ann Oncol. 2014 Dec;25(12):2351-2356. doi: 10.1093/annonc/mdu465. Epub 2014 Oct 1. Ann Oncol. 2014. PMID: 25274615 Free article. Clinical Trial.